AriBio Progresses Novel Alzheimer's Contender Despite Mixed Phase II
But Will Benefits Be Enough?
Executive Summary
Korea's AriBio is poised to file for US Phase III trial approval this year for its novel Alzheimer's candidate and lead asset AR1001, which showed an improvement in cognitive function from baseline at Phase II. But will the benefits over existing therapies be enough to carve a position in the challenging field?
You may also be interested in...
Challenging Alzheimer's: Korean Firms Forge Ahead In Multiple Modalities
In Vivo takes an infographic look at where South Korea stands in the development of a wide-ranging set of drugs for Alzheimer’s disease and which companies are still in the challenging race.
Challenging Alzheimer's: Korean Firms Forge Ahead In Multiple Modalities
Scrip takes an infographic look at where South Korea stands in the development of a wide-ranging set of drugs for Alzheimer’s disease and which companies are still in the challenging race.
Aducanumab Approval Decision Delayed: Could This Be Good News?
Even analysts who still doubt the FDA will approve the anti-amyloid antibody as the first disease-modifying Alzheimer’s treatment said aducanumab’s likelihood of approval has improved.